InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology

Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.

[EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection

Novel approaches in drug discovery using innovative models (PDX & PDX-derived models) to better mimic the situation of the human cancer pathologies.

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance

Read in Communication Biologics (Nature), the data from the exoSTING preclinical program, in which Oncodesign participated (Hepa1-6).

Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1

Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.

Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment

In this study we describe establishment of a luminal breast cancer PDX model with acquired resistance to hormonotherapy

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

[FR] Biotech Info – Oncodesign, la médecine de précision en ligne de mire

[EN] Cancer Vaccine toolbox: innovative strategies for prophylactic or therapeutic vaccines

Oncodesign announces Drug Discovery Cooperation with ViraTherapeutics, a Boehringer Ingelheim subsidiary

Development of an immunogenicity assay for Anti Drug Antibody (ADA)

Immunogenicity assessement for the detection of ADA (Anti Drug Antibody) directed against CpG-D35 using ECL technology (MSD) in serum samples.

[EN] How do we keep you in the race of COVID-19?